Program Signaling and Experimental Therapeutics

程序信号传导和实验治疗

• 批准号: 8340072
• 负责人: George J. Weiner
• 金额: $ 4.9万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-19 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8340072
• 关键词: Androgens; Antineoplastic Agents; Area; Basic Science; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Immunology Science; Cancer Patient; Cell Adhesion; Cell Proliferation; Cell Survival; Cells; Cessation of life; Chemicals; Clinical; Clinical Trials; Collaborations; Computational Biology; Conduct Clinical Trials; Coupled; Development; Drug Delivery Systems; Endometrial Carcinoma; Erinaceidae; Estrogen Receptors; Estrogens; Faculty; Funding; GTP-Binding Proteins; Goals; Grant; Guanosine Triphosphate Phosphohydrolases; Hormonal; Immune response; Individual; Instruction; Integrins; Knowledge; Link; Malignant Neoplasms; Malignant neoplasm of prostate; Modality; Monomeric GTP-Binding Proteins; NF-kappa B; Neoplasm Metastasis; Paper; Pathway interactions; Pharmaceutical Preparations; Pharmacotherapy; Phenotype; Phosphotransferases; Progesterone; Protein Kinase; Publications; Publishing; RNA; RNA Interference; Receptor Signaling; Research; Research Activity; Research Peer Review; Research Personnel; Role; Signal Pathway; Signal Transduction; Signaling Molecule; Signaling Protein; Testing; Therapeutic; Therapeutic Human Experimentation; Translating; Tumor Biology; United States National Institutes of Health; Universities; Vascular Endothelial Growth Factor Receptor; anti-cancer therapeutic; aptamer; base; cancer cell; cancer epidemiology; cancer genetics; cancer immunotherapy; cancer therapy; college; design; high throughput screening; immune RNA; improved; innovation; interest; isoprenoid; malignant breast neoplasm; member; new therapeutic target; next generation; novel; novel strategies; novel therapeutic intervention; novel therapeutics; pre-clinical; programs; receptor; response; small molecule; success; tumor; tumor progression; validation studies

PROJECT SUMMARY (See instructions): Cancer Signaling and Experimental Therapeutics Research in the Cancer Signaling and Experimental Therapeutics (CSET) Program focuses cell signaling pathways and how they impact cancer progression and therapy. The overall goal of the members of this program is to elucidate basic signaling mechanisms relevant to tumor biology and apply this knowledge to the discovery and development of new therapeutic approaches. There are two major overiapping themes within the Program's research: The first theme is Cancer Signaling and is comprised of three interrelated research areas; GTPases and kinases, hormonal signaling and cell adhesion signaling. The second theme is Experimental Therapeutics and is comprised of three interrelated research areas; drug delivery and RNA interference, small molecules and clinical trials. Major accomplishments of the Cancer Signaling and Experimental Therapeutics Program over the past funding period include identification of a new therapeutic target in estrogen receptor signaling in breast cancer, advancement of novel isoprenoid anti-cancer compounds into pre-clinical validation studies, and development of RNA-aptamer-based systemic delivery of RNA-interference in prostate cancer. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. For example, within the program Co-leader Dr. Hohl and Dr. Wiemer have collaborated to develop novel isoprenoid compounds with anti-cancer activity and advance these toward clinical trials and Program Leader Dr. Henry shares separate NCI and NIH grant funding with Drs. Quelle and Lynch, Leaders of the Cancer Genetics and Computational Biology and Cancer Epidemiology programs, respectively and has published recently with Dr. Ballas Leader of the Cancer Immunology and Immunotherapy program. The program consists of 45 members from 7 basic science and 8 clinical departments and 3 Colleges. Peer-reviewed, research funding for this program totals $9.8 million with $3.5 million coming from the NCI. Program members published 339 cancer related papers over the prior funding period. Of these publications, 8% were intraprogrammatic, 27% were interprogrammatic and 2% were both intra and interprogrammatic, for a total of 37% collaborative publications.

项目摘要（请参阅说明）： 癌症信号传导和实验治疗药 癌症信号传导和实验治疗（CSET）计划的研究集中在细胞信号通路以及它们如何影响癌症的进展和治疗。该计划成员的总体目标是阐明与肿瘤生物学相关的基本信号传导机制，并将这些知识应用于新的治疗方法的发现和开发。该计划的研究中有两个主要的主题：第一个主题是癌症信号，由三个相互关联的研究领域组成。 GTPase和激酶，激素信号传导和细胞粘附信号传导。第二个主题是实验性治疗，由三个相互关联的研究领域组成。药物输送和RNA干扰，小分子和临床试验。在过去的资金期间，癌症信号传导和实验治疗计划的主要成就包括鉴定乳腺癌中雌激素受体信号传导的新治疗靶标，新型的异on-类异型抗癌化合物的发展到前临床验证研究中，以及RNA-APTAMER基于RNA-基于RNA的rna rna Interferce in Protostate protostate cancer中的系统。该计划的成员以及其他癌症中心计划的成员之间都有许多过去和现在的富有成效的合作。例如，内部 该计划联合领导者Hohl博士和Wiemer博士合作开发具有抗癌活动的新型类异丙素化合物，并将其推向临床试验和计划负责人亨利（Henry）博士亨利（Henry Sharry）与DRS分开的NCI和NIH Grant Funding。癌症遗传学和计算生物学和癌症流行病学计划的领导者Quelle和Lynch分别与博士一起发表。 巴拉斯癌症免疫学和免疫疗法计划的领导者。该计划由来自7个基础科学和8个临床系和3所大学的45名成员组成。同行评审，该计划的研究资金总计980万美元，NCI的350万美元。计划成员发表了339个与癌症有关的 论文在以前的资金期间。在这些出版物中，有8％的人是内部图表的，有27％的人进行了诠释术语，而2％的术语和诠释式媒介物是共有的，共有37％的合作出版物。